<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurol Genet</journal-id>
<journal-id journal-id-type="hwp">nng</journal-id>
<journal-id journal-id-type="publisher-id">NNG</journal-id>
<journal-title-group>
<journal-title>Neurology: Genetics</journal-title>
</journal-title-group>
<issn pub-type="epub">2376-7839</issn>
<publisher>
<publisher-name>Wolters Kluwer</publisher-name>
<publisher-loc>Baltimore</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27066582</article-id>
<article-id pub-id-type="pmc">4817899</article-id>
<article-id pub-id-type="publisher-id">NG2015000521</article-id>
<article-id pub-id-type="doi">10.1212/NXG.0000000000000045</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>X-inactivation in the clinical phenotype of fragile X premutation carrier sisters</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hall</surname>
<given-names>Deborah A.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Pfizer, Neurocrine</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NIH NS082416, NS074343, NS083054, U24MD006941</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Shapiro Foundation</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Robertson-Dick</surname>
<given-names>Erin E.</given-names>
</name>
<degrees>BA</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O'Keefe</surname>
<given-names>Joan A.</given-names>
</name>
<degrees>PhD, PT</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NIH/Vtesse, Inc. for planning a phase II/III clinical trial for Niemann Pick C: nothing to disclose</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>Rush University Cohen's Fellowship Award: $20,000 Rush University Rush Translational Consortium Award: $50,000</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hadd</surname>
<given-names>Andrew G.</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>Asuragen, Director, 12</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>Integrated DNA Technologies</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development, R43HD060450 and R44HD060450, 2009-2013</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>Asuragen, Inc.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Lili</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Berry-Kravis</surname>
<given-names>Elizabeth</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>(1) Chair of DSMB for Novartis Phase II trial of AFQ056 in fragile X syndrome - 2008-2009 (2) Autism SAB - March 2011 - Novartis (3) Autism SAB - May 2011 - Roche (4) Fragile X Scientific Advisory Board for AFQ056 studies - December 2011 (Chair), June 2012, Novartis (5)Fragile X advisory board - July 2013, Roche (6) Fragile X advisory board - August 2015 - Neurotrope (7) Vteese SAB on Niemann-Pick type C - 2015- 2016</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>(1) Method for assay of CCHS-causing polyalanine repeat expansion for diagnosis</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>(1) The Fragile X Tremor Ataxia Syndrome (FXTAS) , Springer, 2010.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>(1) Novartis (2) Roche (3) Seaside Therapeutics (4) Neurotrope All consulting activities are surrounding the topic of clinical trial design for trials in patients with fragile X syndrome</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>(1) Novartis, Preceptorship on Fragile X Syndrome, February 2012</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>(1) Neuropharm LTD Clinical Trial funding 2008 (2) Seaside Therapeautics Clinical Trial funding - 2008-2013 (3) Roche Clinical Trial funding 2009-2014 (4) Novartis Clinical Trial funding 2010-2014 (5) Neuren Clinical Trial funding 2014-2015 (6) Alcobra Pharmaceuticals Clinical Trial funding 2014-2015 (7) Vtesse, Inc Clinical Trial funding 2015-2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Co-Operative Agreement 9/1/11-8/31/15 0.6 calendar months CDC $12,541/yr directs Fragile X Clinical and Research Consortium Cooperative Agreement The goal of this consortium project is to further develop a registry and database designed to collect longitudinal information from patients with fragile X syndrome to inform clinical practice and public health policy, as well as to facilitate research in the field. Role: Co-PI 1RO1 MH091131-01A1 (M. Losh) 5/1/12-4/30/17 0.6 calendar months NIH/NIMH$80,461/yr directs A Family Genetic Study of Autism and Fragile X Syndrome The goal of this project is to evaluate inheritance of language and social processing deficits in families with fragile X syndrome and autism, and correlate these with molecular parameters related to FMR1 mutations and expression. Role: Co-Investigator, PI at Rush University Site Translational Research Grant (C. Erickson) 3/1/13-2/28/17 0.6 calendar months John Merck Foundation$73,852/ yr directs Acamprosate in Fragile X Syndrome The goals of this 2-site placebo-controlled pilot trial, are to evaluate the safety and efficacy of acamprosate as a mechanistically targeted treatment in fragile X syndrome, as well as to evaluate the effects of acamprosate on novel biomarkers of fragile X syndrome. Role: PI at Rush University Site 1R01 NS082416-01 (D. Hall)4/1/13-3/31/17 0.6 calendar months NIH/NINDS $200,000/yr directs Adult Neurological Phenotypes of Fragile X Gray Zone Expansion The goal of this project is to examine the association of fragile X mental retardation (FMR1) gene gray zone expansion and lack of AGG interspersions in FMR1 with neurological signs and underlying neuropathology among participants in two cohorts of aged individuals in the Religious Orders Study and Memory and Aging Project. Role: Co-Investigator 1R01 HD074346-01A1 (L. Abbeduto) 4/1/13-3/31/18 1.2 calendar months NIH/NICHD $74,904/yr directs Expressive Language Sampling as an Outcome Measure The goal of this 5-site project is to evaluate expressive language sampling as an outcome measure for clinical trials with individuals with FXS or DS and intellectual disability, including establishing feasibility, inter-examiner and inter-site reliability, test-retest reproducibility, clinical validity and responsiveness to change. Role: Co-Investigator, PI at Rush University Site 1RO1 HD (D. Hessl) 1/1/15-12/31/20 0.6 calendar months NIH/NICHD $106,334/yr directs A Cognitive Battery for Intellectual Disabilities The goal of this project is to validate a computer-based cognitive battery, the NIH Toolbox, for use in FXS, DS and developmental disabilities to track responses to treatment, including establishing feasibility, inter-examiner and inter-site reliability, test-retest reproducibility, clinical validity and responsiveness to change. Role: Co-Investigator, PI at Rush University Site 2 U54 HD061222 (A. Percy) 09/30/14-07/31/19 0.12 calendar months NIH/NICHD $1,125,213 (direct) Rett syndrome, MECP2 Duplication, and Rett-related Natural History for the ORDR Rare Disease Clinical Research Consortia (RDCRC) for Rare Disease Clinical Disease Network Rare Disease multisite initiative to provide natural history studies leading to possible therapies for Rett syndrome, MECP2 Duplication Disorder, and Rett-related Disorders Natural History. Role: Co-Investigator 1 U54 NS092090-01 (M. Sahin)09/30/14-07/31/19 0.6 calendar months NIH/NINDS Developmental Synaptopathies Associated with TSC, PTEN and SHANK3 Mutations Rare Disease Clinical Research Consortia (RDCRC) for Rare Disease Clinical Disease Network Rare disease multi-site initiative to provide natural history data for Phelan-McDermid syndrome (PMS), TSC, and PTEN-associated syndromes. The Phelan-McDermid project will be run at Rush University site and will collect natural history on PMS laying the groundwork for development of targeted treatments for PMS.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From the Department of Neurological Sciences (D.A.H., E.B.-K.), Department of Anatomy and Cell Biology (E.E.R.-D., J.A.O.), Department of Biochemistry (L.Z., E.B.-K.), and Department of Pediatrics (E.B.-K.), Rush University, Chicago, IL; and Asuragen, Inc. (A.G.H.), Austin, TX.</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence to Dr. Hall: <email>Deborah_A_Hall@rush.edu</email></corresp>
<fn fn-type="financial-disclosure">
<p>Funding information and disclosures are provided at the end of the article. Go to <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000045">Neurology.org/ng</ext-link> for full disclosure forms. The Article Processing Charge was paid by the authors.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>03</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>03</day>
<month>2</month>
<year>2016</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>2</volume>
<issue>1</issue>
<elocation-id>e45</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>6</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>11</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>© 2016 American Academy of Neurology</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p>
</license>
</permissions>
<self-uri xlink:href="NG2015000521.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<abstract>
<sec>
<title>Objective:</title>
<p>The purpose of this study is to describe a case series of 4 sisters with discordant clinical phenotypes associated with fragile X–associated tremor/ataxia syndrome (FXTAS) that may be explained by varying CGG repeat sizes and activation ratios (ARs) (the ratio of cells carrying the normal fragile X mental retardation 1 [<italic>FMR1</italic>] allele on the active X chromosome).</p>
</sec>
<sec>
<title>Methods:</title>
<p>Four sisters with premutation size <italic>FMR1</italic> gene repeats underwent detailed clinical characterization. CGG repeat length was determined by PCR, and AR was determined using a newly developed commercial methylation PCR assay and was compared with the results from Southern blot with densitometric image analysis.</p>
</sec>
<sec>
<title>Results:</title>
<p>Sister 1 had the largest CGG expansion (82) and the lowest AR (12%), with the most severe clinical presentation. Sister 2 had a lower CGG expansion (70) and an AR of 10% but had a milder clinical presentation.Sister 3 had a similar CGG expansion (79) but a slightly higher AR of 15% and less neurologic involvement. Sister 4 had a similar CGG expansion size of 80 but had the largest AR (40%) and was the only sister not to be affected by FXTAS or have any neurologic signs on examination.</p>
</sec>
<sec>
<title>Conclusions:</title>
<p>These results suggest that premutation carrier women who have higher ARs may be less likely to show manifestations of FXTAS. If larger studies show similar patterns, AR data could potentially be beneficial to supplement CGG repeat size when counseling premutation carrier women in the clinic.</p>
</sec>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>Fragile X–associated tremor/ataxia syndrome (FXTAS) is caused by a “premutation” size 55 to 200 CGG repeat expansion in the fragile X mental retardation 1 (<italic>FMR1</italic>) gene.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> Individuals with a normal <italic>FMR1</italic> gene have fewer than 41 CGG repeats at the 5′ untranslated region of the gene. Three discrete disorders that increase morbidity of individuals carrying an expansion have been characterized, each associated with different lengths of the CGG tract. Fragile X syndrome (FXS), the most common inherited cause of intellectual disability in boys, results from a CGG expansion of &gt;200 repeats (full mutation) and is characterized by neurocognitive and developmental abnormalities, including a high incidence of autism, anxiety, and attention-deficit/hyperactivity disorder. FXTAS, first described in 2001, is caused by a “premutation” with a CGG length of 55 to 200 repeats and manifests as kinetic tremor, cerebellar gait ataxia, executive dysfunction, and psychiatric symptoms in premutation carriers, typically over age 55.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> Although premutation carrier men are more frequently and severely affected, recent studies report more neurologic involvement in women than was previously believed, despite the presence of a normal <italic>FMR1</italic> allele on the other X chromosome.<sup><xref ref-type="bibr" rid="R2">2</xref></sup> A third disorder, fragile X–associated primary ovarian insufficiency (FXPOI), occurs in approximately 20% of women who carry a premutation size allele. Women with FXPOI experience ovarian dysfunction and early estrogen deficiency resulting in premature menopause.<sup><xref ref-type="bibr" rid="R3">3</xref></sup> In addition, premutation carrier women have been reported to have a host of milder neurologic signs and other medical illnesses that have not yet been well defined.<sup><xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref></sup></p>
<p>Because of the observation that women with FXTAS show a milder clinical presentation of the disease than do men, attention has been given to the possible role of X-inactivation in mediating the phenotypic outcome of premutation carrier women. X chromosome inactivation is the transcriptional silencing of 1 X chromosome in the somatic cells of women. For premutation carrier women, this means that a percentage of cells will contain an active abnormal <italic>FMR1</italic> allele and the remaining cells will contain an active normal <italic>FMR1</italic> allele. On average, 50% of cells from a carrier woman should contain an active premutation allele and 50% an active normal allele, but some individuals have skewing of this ratio such that the percentages are unequal.<sup><xref ref-type="bibr" rid="R6">6</xref></sup> It has been hypothesized that variation in the activation ratio (AR) (the ratio of cells carrying the normal <italic>FMR1</italic> allele on the active X chromosome) may result in substantial phenotypic heterogeneity among premutation carrier women.</p>
<p>There are few published studies correlating disease severity and AR in FXTAS. A case report described 2 sisters with similar premutation expansion sizes (69 and 83) but differing ARs.<sup><xref ref-type="bibr" rid="R7">7</xref></sup> The sister with 78% AR did not meet the clinical criteria for FXTAS, whereas the sister with 29% AR had definite FXTAS. A much larger study including 82 premutation carrier women demonstrated that a lower AR in association with increasing CGG repeats was correlated with the risk for FXTAS and symptom severity.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> Recently, we reported that higher AR was associated with better posturography balance scores in carrier women with and without FXTAS.<sup><xref ref-type="bibr" rid="R9">9</xref></sup></p>
<p>The current case series describes a family of 4 sisters with similar premutation size <italic>FMR1</italic> alleles. The AR was measured in each sister, and clinical phenotypes were compared using these ratios. The purpose of a detailed study of this family was to determine whether AR, in addition to CGG repeat size, could account for the varying neurologic phenotypes.</p>
<sec id="s1" sec-type="methods">
<title>METHODS</title>
<sec id="s1-1">
<title>Standard protocol approvals, registrations, and patient consents.</title>
<p>The sisters were recruited through the Fragile X–Associated Disorders Program at Rush University. This study was approved by the Rush University Institutional Review Board.</p>
</sec>
<sec id="s1-2">
<title>Clinical and molecular methods.</title>
<p>All sisters were scored using the FXTAS Rating Scale (FXTAS-RS), which rates tremor, postural sway, gait, parkinsonism, coordination, dystonia, speech, and oculomotor deficits to assess the presence and severity of FXTAS signs.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> The scale was created using items from the Unified Parkinson's Disease Rating Scale, the Clinical Rating Scale for Tremor, the International Cooperative Ataxia Rating Scale, and a tandem item from the Unified Huntington's Disease Rating Scale.<sup><xref ref-type="bibr" rid="R10">10</xref><xref ref-type="bibr" rid="R11">–</xref><xref ref-type="bibr" rid="R13">13</xref></sup> Medical history, neurologic examination, and MRI, when available, were used to diagnose FXTAS according to clinical and radiologic criteria (<xref ref-type="table" rid="T1">table 1</xref>).<sup><xref ref-type="bibr" rid="R14">14</xref></sup> Two sisters underwent additional posturography testing using the Neurocom Smart Balance Master system (Natus Medical, Pleasanton, CA)<sup><xref ref-type="bibr" rid="R15">15</xref></sup> and gait analysis using inertial sensors.<sup><xref ref-type="bibr" rid="R16">16</xref></sup></p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Diagnostic criteria for fragile X-associated tremor/ataxia syndrome</p>
</caption>
<graphic xlink:href="NG2015000521TT1"></graphic>
</table-wrap>
<p>DNA was isolated from blood samples, and molecular testing on the samples was performed at the Rush University Molecular Diagnostic Laboratory. <italic>FMR1</italic> PCR with quantification of allele-specific CGG repeat length and identification of AGG interspersions<sup><xref ref-type="bibr" rid="R17">17</xref>,<xref ref-type="bibr" rid="R18">18</xref></sup> and AR measurement using a new methylation PCR (mPCR) assay<sup><xref ref-type="bibr" rid="R19">19</xref></sup> were performed using commercially available kits (Asuragen, Inc., Austin, TX). The <italic>FMR1</italic> mPCR<sup><xref ref-type="bibr" rid="R19">19</xref></sup> was performed according to the manufacturer's instructions on 20 to 80 ng of DNA quantified with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA). The mPCR methodology involved gene-specific PCR of genomic DNA that was treated with <italic>Hpa</italic> II (methylation-sensitive) and amplified with hexachlorofluorescein (HEX)-specific primers (amplifies only the methylated allele) or mock-treated and amplified with fluorescein (FAM)-specific primers (amplifies both alleles), followed by separation and visualization by capillary electrophoresis. The <italic>FMR1</italic> (DNA) locus was analyzed by Southern blot with probe StB12.3,<sup><xref ref-type="bibr" rid="R20">20</xref></sup> following <italic>Eco</italic> RI/<italic>Eag</italic> I digestion. ARs for the normal allele were quantified by densitometric scanning of bands corresponding to unmethyated (active) DNA on the Southern blot. AR was calculated as signal from the normal-containing band divided by total signal in both the premutation-containing and normal bands with densitometric image analysis, as described in previous studies.<sup><xref ref-type="bibr" rid="R7">7</xref></sup> Correspondingly, ARs using mPCR were determined relative to the unmethylated component of the normal allele, as described previously.<sup><xref ref-type="bibr" rid="R19">19</xref></sup> The percentage methylation on the normal allele is proportional to the ratio of the total peak area in the HEX relative to the FAM channel. Thus, the AR is 1 − (HEX area/FAM area) for that allele. AR results were confirmed by Southern blot with densitometric image analysis as described in previous studies.<sup><xref ref-type="bibr" rid="R7">7</xref></sup></p>
</sec>
</sec>
<sec id="s2" sec-type="results">
<title>RESULTS</title>
<sec id="s2-1">
<title>Case reports.</title>
<p>Four sisters are presented to illustrate phenotypic variability, CGG repeat size, and AR (<xref ref-type="table" rid="T2">table 2</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>Clinical, molecular, and radiographic features</p>
</caption>
<graphic xlink:href="NG2015000521TT2"></graphic>
</table-wrap>
<sec id="s2-1-1">
<title>Case 1.</title>
<p>A 79-year-old woman developed balance problems at age 74. She had 3 sisters and 1 brother, as well as a nephew, a daughter, and a granddaughter with FXS (<xref ref-type="fig" rid="F1">figure 1</xref>). Examination at age 75 revealed transient end-gaze nystagmus and absent reflexes in all 4 extremities. She had anterocollis, mild tremor, and dysdiadochokinesia in her left hand, increased tone in the right upper extremity, and bradykinesia in her left leg. She was unable to stand or walk in tandem without falling. Posturography revealed significant abnormalities in the vestibular control of balance, reduced limits of postural stability, and delayed automatic postural reflexes. Her FXTAS-RS score was 23 (<xref ref-type="fig" rid="F2">figure 2</xref>). MRI of the brain showed severe global and cerebellar atrophy, periventricular and deep white matter ischemia, and white matter hyperintensities in the pons (<xref ref-type="fig" rid="F3">figure 3</xref>). Her <italic>FMR1</italic> CGG repeat sizes were 30 and 82 with an AR of 12%, and she was diagnosed with definite FXTAS.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Pedigree</title>
<p>Abbreviations: AR = activation ratio; FXTAS = fragile X-associated tremor/ataxia syndrome.</p>
</caption>
<graphic xlink:href="NG2015000521FF1"></graphic>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>FXTAS Rating Scale scores for case 1</title>
<p>Fragile X-associated tremor/ataxia syndrome (FXTAS) Rating Scale scores for case 1 show gradual progression over time. Worsening of the score was seen when the patient was admitted for psychosis at 10 months. Upon treatment of the psychosis and aggressive rehabilitation, the score improved. The score peaks again at 21 months when she had surgery. The last score was right before her death.</p>
</caption>
<graphic xlink:href="NG2015000521FF2"></graphic>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>MRI for case 1</title>
<p>(A) T2-weighted axial fluid-attenuated inversion recovery brain MRI showing white matter hyperintensities in the cortex. (B) T2-weighted axial brain MRI showing white matter hyperintensities in the pons.</p>
</caption>
<graphic xlink:href="NG2015000521FF3"></graphic>
</fig>
<p>At age 76, she fell twice and on examination her ataxia and tremor had worsened, with an increased FXTAS-RS score of 27. She then developed mild cognitive impairment, hallucinations, and paranoid delusions. Her examination showed continued postural instability, wide-based gait and ataxia, festination, short steps, difficulty with turns, and ineffective use of walker. At age 77, her Mini-Mental State Examination score was 5/30,<sup><xref ref-type="bibr" rid="R21">21</xref></sup> but her FXTAS motor signs were stable. Memantine was prescribed to slow her cognitive decline. Over the next 2 years, her FXTAS-RS score continued to worsen, reaching 72. However, she appeared unaware of her balance difficulties; when self-reporting her balance confidence for numerous activities of daily living, she scored in the range that represents a high level of perceived balance function, despite the fact that she had fallen several times in the previous year. She died at age 80 due to a presumed pulmonary embolus.</p>
</sec>
<sec id="s2-1-2">
<title>Case 2.</title>
<p>The first sister of case 1 was a 75-year-old woman who developed problems with balance and memory at age 72. She had fallen recently, and she described neck pain and numbness in the toes. Associated symptoms included problems with memory and depression starting at age 71. Her medical history was remarkable for FXPOI. She had a daughter who was healthy and a son with a learning disability and unknown gene status. Examination revealed persistent horizontal gaze-evoked nystagmus, mild dysarthria, mild left hand action tremor, and cervical dystonia. MRI of the brain showed scattered deep white matter hyperintensities. Her FXTAS-RS score was 15, but she met clinical criteria for possible FXTAS. Her <italic>FMR1</italic> CGG repeat sizes were 30 and 70 with an AR of 10%.</p>
</sec>
<sec id="s2-1-3">
<title>Case 3.</title>
<p>The second sister of case 1 was a 66-year-old woman who presented with balance problems and dizziness. She described curling of her toes on the right foot, turning in of the right foot when walking, and numbness and tingling of the legs. She reported short-term memory problems, anxiety, and occasional depression. Neurologic examination showed increased stance, increased body sway with her eyes closed, and difficulty with tandem gait. Vibration was decreased by 50% in her feet. Her FXTAS-RS score was 11. Her <italic>FMR1</italic> CGG repeat sizes were 30 and 79 with an AR of 15%. She met clinical criteria for possible FXTAS, although she did not undergo brain MRI.</p>
</sec>
<sec id="s2-1-4">
<title>Case 4.</title>
<p>The third sister of case 1 was a 79-year-old woman with no medical problems and no neurologic symptoms. She took no prescription medications and was a competitive dancer and body builder and taught exercise classes. Her neurologic examination, posturography, and gait testing were normal. Her FXTAS-RS score was 7, normal for her age. Her <italic>FMR1</italic> CGG repeat sizes were 30 and 80 with an AR of 40%.</p>
</sec>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>DISCUSSION</title>
<p>This case series describes a family of 4 sisters with premutation size <italic>FMR1</italic> alleles who presented with a high degree of phenotypic variability (<xref ref-type="table" rid="T2">table 2</xref>). Case 1 had the largest CGG expansion, lowest AR, and the most severe clinical presentation. Case 2 had an AR similar to that of case 1 but a lower CGG expansion and milder neurologic symptoms. Case 3 had a CGG expansion in between cases 1 and 2 but a slightly higher AR and less neurologic involvement. Case 4 was the only sister not affected by FXTAS despite having a similar CGG repeat expansion; this may be attributed to her having the largest AR of the family. Although the AR varies only between 10% and 40% in these sisters, it is in the expected direction: the sister with the lowest AR has the most severe neurologic signs and the sister with the highest ratio has no signs of FXTAS. The difference in ratios alone does not seem to be sufficient to explain such a large difference in outcomes and may suggest that another unknown secondary gene effect plays a role as well.</p>
<p>Individuals harboring premutation alleles produce increased levels of expanded CGG-containing <italic>FMR1</italic> mRNA, which is believed to result in neurologic disease due to RNA toxicity.<sup><xref ref-type="bibr" rid="R22">22</xref></sup> Severity of motor impairment has been related to CGG repeat length in women, but only when controlling for AR.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> As such, it has been observed that sisters with similar CGG expansions may have highly variable phenotypic presentations, likely due to differences in AR.<sup><xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R23">23</xref></sup></p>
<p>There are several limitations to this study. First, it describes only 1 family of sisters rather than a series. Second, the FXTAS diagnostic criteria (<xref ref-type="table" rid="T1">table 1</xref>) require a brain MRI to make a probable or definite FXTAS diagnosis. Cases 3 and 4 were not imaged because of mild or absent neurologic signs, so only a diagnosis of possible FXTAS could be reached in case 3. The presence of major radiologic criteria, such as the middle cerebellar peduncle sign, on imaging would increase the diagnostic certainty to definite despite the low FXTAS-RS score.</p>
<p>This case series suggests a possible role for AR in conferring risk for FXTAS and its severity in premutation carrier women. In current practice, counseling regarding premutation-related disorders is based on CGG repeat size alone. The addition of AR results may provide information that could inform the clinician regarding current or future phenotypes. Much larger studies are warranted to determine the true utility of this molecular measure in informing the clinician.</p>
</sec>
</body>
<back>
<ack>
<title>ACKNOWLEDGMENT</title>
<p>The authors thank Gary J. Latham for review of the manuscript and Stela Filipovic-Sadic for technical support.</p>
</ack>
<sec sec-type="contributions">
<title>AUTHOR CONTRIBUTIONS</title>
<p content-type="contributions">Deborah Hall: clinical data collection; drafting/revising the manuscript. Erin Robertson-Dick: drafting/revising the manuscript. Joan O'Keefe: clinical data collection; revising the manuscript. Andrew Hadd: revising the manuscript. Lili Zhou: clinical data collection; revising the manuscript. Elizabeth Berry-Kravis: clinical data collection; revising the manuscript.</p>
</sec>
<sec sec-type="funding">
<title>STUDY FUNDING</title>
<p content-type="funding">This work was supported in part by awards from the Rush Translational Science Consortium (D.A.H.), the Rush Cohn Fellowship award (J.A.O.), and the Eunice Kennedy Shriver <funding-source>National Institute of Child Health &amp; Human Development</funding-source> (R44 HD060450-02, A.G.H.).</p>
</sec>
<sec sec-type="disclosure">
<title>DISCLOSURE</title>
<p content-type="disclosure">Deborah A. Hall has received research funds from <funding-source>NIH</funding-source>, <funding-source>NINDS</funding-source>, Shapiro Foundation, National Parkinson Disease Foundation, Pfizer, and Neurocrine. Erin Robertson-Dick reports no disclosures. Joan A. O'Keefe has served on the scientific advisory board of <funding-source>NIH</funding-source>/Vtesse, Inc. and has received research support from Rush University Cohen's Fellowship Award and Rush University Rush Translational Consortium Award. Andrew Hadd is a full-time employee and options holder in Asuragen, Inc.; has been a consultant for Integrated DNA Technologies; has received research support from the Eunice Kennedy Shriver <funding-source>National Institute of Child Health &amp; Human Development</funding-source>; and holds stock/stock options/board of directors compensation in Asuragen, Inc. Lili Zhou has received funding from Roche for diagnostic <italic>FMR1</italic> testing during clinical trials in FXS and has current grant funding from <funding-source>NIH</funding-source>. Elizabeth Berry-Kravis has served as the Chair of DSMB for Novartis Phase II trial of AFQ056 in fragile X syndrome; has served on the scientific advisory boards of Novartis, Roche, Neurotrope, and Vteese; holds a patent for Method for assay of CCHS-causing polyalanine repeat expansion for diagnosis; receives publishing royalties for The Fragile X Tremor Ataxia Syndrome (FXTAS), Springer, 2010; has been a consultant for Novartis, Roche, Seaside Therapeutics, and Neurotrope; was part of a Novartis Preceptorship on Fragile X Syndrome in February 2012; and has received research support from Neuropharm LTD, Seaside Therapeutics, Roche, Novartis, Neuren, Alcobra, Vtesse, Asuragen Inc., CDC, <funding-source>NIH</funding-source>, John Merck Fund, the Hope for Hayley Foundation, and the FRAXA Research Foundation. Go to <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000045">Neurology.org/ng</ext-link> for full disclosure forms.</p>
</sec>
<glossary>
<title>GLOSSARY</title>
<def-list>
<def-item>
<term id="G1">AR</term>
<def>
<p>activation ratio</p>
</def>
</def-item>
<def-item>
<term id="G2">FAM</term>
<def>
<p>fluorescein</p>
</def>
</def-item>
<def-item>
<term id="G3">
<italic>FMR1</italic>
</term>
<def>
<p>fragile X mental retardation 1</p>
</def>
</def-item>
<def-item>
<term id="G4">FXPOI</term>
<def>
<p>fragile X–associated primary ovarian insufficiency</p>
</def>
</def-item>
<def-item>
<term id="G5">FXS</term>
<def>
<p>fragile X syndrome</p>
</def>
</def-item>
<def-item>
<term id="G6">FXTAS</term>
<def>
<p>fragile X–associated tremor/ataxia syndrome</p>
</def>
</def-item>
<def-item>
<term id="G7">FXTAS-RS</term>
<def>
<p>FXTAS Rating Scale</p>
</def>
</def-item>
<def-item>
<term id="G8">HEX</term>
<def>
<p>hexachlorofluorescein</p>
</def>
</def-item>
<def-item>
<term id="G9">mPCR</term>
<def>
<p>methylation PCR</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>REFERENCES</title>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagerman</surname><given-names>RJ</given-names></name><name><surname>Leehey</surname><given-names>M</given-names></name><name><surname>Heinrichs</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X</article-title>. <source/>Neurology
<year>2001</year>;<volume>57</volume>:<fpage>127</fpage>–<lpage>130</lpage>.<pub-id pub-id-type="pmid">11445641</pub-id></mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffey</surname><given-names>SM</given-names></name><name><surname>Cook</surname><given-names>K</given-names></name><name><surname>Tartaglia</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Expanded clinical phenotype of women with the FMR1 premutation</article-title>. <source/>Am J Med Genet A
<year>2008</year>;<volume>146A</volume>:<fpage>1009</fpage>–<lpage>1016</lpage>.<pub-id pub-id-type="pmid">18348275</pub-id></mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>SL</given-names></name><name><surname>Curnow</surname><given-names>EC</given-names></name><name><surname>Easley</surname><given-names>CA</given-names></name><etal></etal></person-group>
<article-title>Use of model systems to understand the etiology of fragile X-associated primary ovarian insufficiency (FXPOI)</article-title>. <source/>J Neurodev Disord
<year>2014</year>;<volume>6</volume>:<fpage>26</fpage>.<pub-id pub-id-type="pmid">25147583</pub-id></mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>JE</given-names></name><name><surname>Rohr</surname><given-names>JK</given-names></name><name><surname>Sherman</surname><given-names>SL</given-names></name></person-group>
<article-title>Co-occurring diagnoses among FMR1 premutation allele carriers</article-title>. <source/>Clin Genet
<year>2010</year>;<volume>77</volume>:<fpage>374</fpage>–<lpage>381</lpage>.<pub-id pub-id-type="pmid">20059484</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>D</given-names></name><name><surname>Todorova-Koteva</surname><given-names>K</given-names></name><name><surname>Pandya</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Neurological and endocrine phenotypes of fragile X carrier women</article-title>. <source/>Clin Genet
<year>2016</year>;<volume>89</volume>:<fpage>60</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="pmid">26212380</pub-id></mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Shete</surname><given-names>S</given-names></name></person-group>
<article-title>X-chromosome genetic association test accounting for X-inactivation, skewed X-inactivation, and escape from X-inactivation</article-title>. <source/>Genet Epidemiol
<year>2014</year>;<volume>38</volume>:<fpage>483</fpage>–<lpage>493</lpage>.<pub-id pub-id-type="pmid">25043884</pub-id></mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry-Kravis</surname><given-names>E</given-names></name><name><surname>Potanos</surname><given-names>K</given-names></name><name><surname>Weinberg</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name></person-group>
<article-title>Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation</article-title>. <source/>Ann Neurol
<year>2005</year>;<volume>57</volume>:<fpage>144</fpage>–<lpage>147</lpage>.<pub-id pub-id-type="pmid">15622531</pub-id></mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leehey</surname><given-names>MA</given-names></name><name><surname>Berry-Kravis</surname><given-names>E</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><etal></etal></person-group>
<article-title>FMR1 CGG repeat length predicts motor dysfunction in premutation carriers</article-title>. <source/>Neurology
<year>2008</year>;<volume>70</volume>:<fpage>1397</fpage>–<lpage>1402</lpage>.<pub-id pub-id-type="pmid">18057320</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fahn</surname><given-names>S</given-names></name><name><surname>Elton</surname><given-names>RL</given-names></name></person-group>; <collab>UPDRS Program Members</collab>. <article-title>Unified Parkinson's Disease Rating Scale</article-title>. In: <person-group person-group-type="editor"><name><surname>Fahn</surname><given-names>S</given-names></name><name><surname>Marsden</surname><given-names>CD</given-names></name><name><surname>Goldstein</surname><given-names>M</given-names></name><name><surname>Calne</surname><given-names>DB</given-names></name></person-group>, editors. <source/>Recent Developments in Parkinson's Disease, <volume>vol 2</volume>
<publisher-loc>Florham Park, NJ</publisher-loc>: <publisher-name>Macmillan Healthcare Information</publisher-name>; <year>1987</year>:<fpage>153</fpage>–<lpage>163</lpage>, <comment>293–304</comment>.</mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bain</surname><given-names>PG</given-names></name><name><surname>Findley</surname><given-names>LG</given-names></name><name><surname>Atchison</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Assessing tremor severity</article-title>. <source/>J Neurol Neurosurg Psychiatry
<year>1993</year>;<volume>56</volume>:<fpage>868</fpage>–<lpage>873</lpage>.<pub-id pub-id-type="pmid">8350102</pub-id></mixed-citation>
</ref>
<ref id="R11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trouillas</surname><given-names>P</given-names></name><name><surname>Takayanagi</surname><given-names>T</given-names></name><name><surname>Hallett</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>International Cooperative Ataxia Rating Scale for the pharmacological assessment of the cerebellar syndrome</article-title>. <source/>J Neurol Sci
<year>1997</year>;<volume>145</volume>:<fpage>205</fpage>–<lpage>211</lpage>.<pub-id pub-id-type="pmid">9094050</pub-id></mixed-citation>
</ref>
<ref id="R12">
<label>12.</label>
<mixed-citation publication-type="journal"><collab>Huntington Study Group</collab>. <article-title>Unified Huntington's Disease Rating Scale: reliability and consistency</article-title>. <source/>Mov Disord
<year>1996</year>;<volume>11</volume>:<fpage>136</fpage>–<lpage>142</lpage>.<pub-id pub-id-type="pmid">8684382</pub-id></mixed-citation>
</ref>
<ref id="R13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacquemont</surname><given-names>S</given-names></name><name><surname>Hagerman</surname><given-names>RJ</given-names></name><name><surname>Leehey</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates</article-title>. <source/>Am J Hum Genet
<year>2003</year>;<volume>72</volume>:<fpage>869</fpage>–<lpage>878</lpage>.<pub-id pub-id-type="pmid">12638084</pub-id></mixed-citation>
</ref>
<ref id="R14">
<label>14.</label>
<mixed-citation publication-type="book"><collab>Natus Medical Incorporated</collab>. <source/>Balance Manager Systems, Clinical Interpretations Guide, Computerized Dynamic Posturography. <publisher-loc>Pleasanton, CA</publisher-loc>: <publisher-name>Natus Medical Incorporated</publisher-name>; <year>2009</year>:<comment>D102559–00D:139–145</comment>.</mixed-citation>
</ref>
<ref id="R15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Keefe</surname><given-names>JA</given-names></name><name><surname>Robertson-Dick</surname><given-names>E</given-names></name><name><surname>Dunn</surname><given-names>EJ</given-names></name><etal></etal></person-group>
<article-title>Characterization and early detection of balance deficits in fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>. <source/>Cerebellum
<year>2015</year>;<volume>14</volume>:<fpage>650</fpage>–<lpage>662</lpage>.<pub-id pub-id-type="pmid">25763861</pub-id></mixed-citation>
</ref>
<ref id="R16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salarian</surname><given-names>A</given-names></name><name><surname>Horak</surname><given-names>FB</given-names></name><name><surname>Zampieri</surname><given-names>C</given-names></name><name><surname>Carlson-Kuhta</surname><given-names>P</given-names></name><name><surname>Nutt</surname><given-names>JG</given-names></name><name><surname>Aminian</surname><given-names>K</given-names></name></person-group>
<article-title>iTUG, a sensitive and reliable measure of mobility</article-title>. <source/>IEEE Trans Neural Syst Rehabil Eng
<year>2010</year>;<volume>18</volume>:<fpage>303</fpage>–<lpage>310</lpage>.<pub-id pub-id-type="pmid">20388604</pub-id></mixed-citation>
</ref>
<ref id="R17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filipovic-Sadic</surname><given-names>S</given-names></name><name><surname>Sah</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome</article-title>. <source/>Clin Chem
<year>2010</year>;<volume>56</volume>:<fpage>399</fpage>–<lpage>408</lpage>.<pub-id pub-id-type="pmid">20056738</pub-id></mixed-citation>
</ref>
<ref id="R18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Tassone</surname><given-names>F</given-names></name><name><surname>Berman</surname><given-names>RF</given-names></name><etal></etal></person-group>
<article-title>Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration</article-title>. <source/>Hum Mol Genet
<year>2010</year>;<volume>19</volume>:<fpage>196</fpage>–<lpage>208</lpage>.<pub-id pub-id-type="pmid">19846466</pub-id></mixed-citation>
</ref>
<ref id="R19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Hadd</surname><given-names>AG</given-names></name><name><surname>Sah</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>High-resolution methylation polymerase chain reaction for fragile X analysis: evidence for novel FMR1 methylation patterns undetected in Southern blot analyses</article-title>. <source/>Genet Med
<year>2011</year>;<volume>3</volume>:<fpage>528</fpage>–<lpage>538</lpage>.<pub-id pub-id-type="pmid">21430544</pub-id></mixed-citation>
</ref>
<ref id="R20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousseau</surname><given-names>F</given-names></name><name><surname>Heitz</surname><given-names>D</given-names></name><name><surname>Biancalana</surname><given-names>V</given-names></name><etal></etal></person-group>
<article-title>Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation</article-title>. <source/>N Engl J Med
<year>1991</year>;<volume>325</volume>:<fpage>1673</fpage>–<lpage>1681</lpage>.<pub-id pub-id-type="pmid">1944467</pub-id></mixed-citation>
</ref>
<ref id="R21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group>
<article-title>“Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician</article-title>. <source/>J Psychiatr Res
<year>1975</year>;<volume>12</volume>:<fpage>189</fpage>–<lpage>198</lpage>.<pub-id pub-id-type="pmid">1202204</pub-id></mixed-citation>
</ref>
<ref id="R22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagerman</surname><given-names>R</given-names></name><name><surname>Hagerman</surname><given-names>P</given-names></name></person-group>
<article-title>Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome</article-title>. <source/>Lancet Neurol
<year>2013</year>;<volume>12</volume>:<fpage>786</fpage>–<lpage>798</lpage>.<pub-id pub-id-type="pmid">23867198</pub-id></mixed-citation>
</ref>
<ref id="R23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Revenga</surname><given-names>L</given-names></name><name><surname>Pagonabarraga</surname><given-names>J</given-names></name><name><surname>Gómez-Anson</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Motor and mental dysfunction in mother-daughter transmitted FXTAS</article-title>. <source/>Neurology
<year>2010</year>;<volume>75</volume>:<fpage>1370</fpage>–<lpage>1376</lpage>.<pub-id pub-id-type="pmid">20938029</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>